2',3'-Di-O-acetyl-5'-deoxy-5-fluoro-N4-(pentoxycarbonxyl)cytidine

2',3'-Di-O-acetyl-5'-deoxy-5-fluoro-N4-(pentoxycarbonxyl)cytidine, also known as DFP-10917, is a novel nucleoside analogue that has demonstrated potent antitumor activity in preclinical studies. This compound is a prodrug of 5-fluorouracil, which is a widely used chemotherapeutic agent for the treatment of various types of cancer. DFP-10917 is designed to selectively target cancer cells while minimizing toxicity to normal cells. The chemical structure of DFP-10917 consists of a cytidine base modified with a pentoxycarbonyl group at the N4 position and a 5-fluoro substituent at the 5' position. The cytidine base is an essential component of DNA and RNA, and its modification with the pentoxycarbonyl and 5-fluoro groups enhances the compound's antitumor activity by interfering with DNA synthesis and repair. DFP-10917 is primarily administered intravenously and undergoes rapid conversion to 5-fluorouracil in the body. The prodrug form of DFP-10917 allows for targeted delivery of the active drug to cancer cells, which may enhance its efficacy and reduce side effects. Preclinical studies have shown that DFP-10917 is effective against a range of cancer types, including breast, lung, and colon cancers. In summary, DFP-10917 is a promising antitumor agent that has shown potent activity against various types of cancer in preclinical studies. Its unique chemical structure and prodrug formulation may offer advantages over existing chemotherapy drugs by providing targeted delivery and minimizing toxicity to normal cells. Further clinical development of DFP-10917 is warranted to determine its safety and efficacy in human patients.